Source | Inclusion criteria | Exclusion criteria | No. of patients | Interventions | Primary outcome |
---|---|---|---|---|---|
PEXIVAS 2020 [17] | New or relapsing GPA or MPA; PR3 or MPO-ANCA positive; renal or pulmonary involvement | Age < 15 year; pregnancy; vasculitis other than MPA or GPA; anti-GBM disease; dialysis for greater than 21 days prior to randomisation or prior renal transplant; prior PE in 3 months; use of CYC, rituximab, or high dose GC prior to randomisation* | 704, MPA or GPA (no data of percentage) | PE†[(a) centrifugation or filter separation, (b) 3–5% albumin or fresh frozen plasma, (c) 60 mL/kg, (d) 7 sessions over 14 days] vs no PE | The composite of the death or ESRD |
Szpirt et al., 2011 [28] | At least 2 of the following 3 criteria (i) WG-clinical manifestations at least 2 organs, (ii) histology-proven WG, (iii) positive ‘C-ANCA/PR3-ANCA’ | No description | 32 GPA (100%) | PE†[(a) filter separation, (b) 3% albumin in Ringer’s lactate, (c) 4 L, (d) 6 sessions every other day. If high ANCA titre after 6 sessions, 3–6 sessions were added.] vs no PE | Renal progression, ESRD, improvement of renal function, remission, relapse, death |
Zäuner et al., 2002 [31] | The clinical picture of type II or III RPGN [33]; Had not treated previously with immunosuppression or PE. | Type I RPGN [33] | 39, MPA (18%), GPA (67%) or type II RPGN (15%) | PE†[(a) no description, (b) fresh frozen plasma, (c) 40 mL/kg, (d) the mean 6 sessions (range, 3–12).] vs no PE | The composite of the death or ESRD, renal function, extrarenal manifestation, adverse events |
Pusey et al., 1991 [30] | Impaired renal function; Focal necrotizing glomerulonephritis with crescents; a diagnosis of WG, MPA or IRPGN | Concomitant vasculitis other than AAV; anti-GBM disease; underlying chronic glomerulonephritis; previously treated with intravenous GC, oral CYC or PE* | 52, MPA (42%), GPA (48%) or IRPGN (10%)‡ | PE†[(a) centrifugation, (b) 5% albumin, (c) 4 L, (d) 5 times within the first week. Mean 9 sessions (range 5–25).] vs no PE | ESRD, death, serum creatinine, improvement of renal function |